Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms

  1. Juan Manuel Carreño
  2. Damodara Rao Mendu
  3. Viviana Simon
  4. Masood A. Shariff
  5. Gagandeep Singh
  6. Vidya Menon
  7. Florian Krammer

Reviewed by

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.isci.2021.102937
  2. ScreenIT

    SciScore for 10.1101/2021.02.24.21252340: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: Study participants and human samples The samples used for the longitudinal study, were part of a cross sectional cohort of healthcare by the Institutional Review Board (IRB#20-009).
    Consent: Informed consent was obtained prior to Phase 1 sample collection.
    Randomizationnot detected.
    BlindingAll serum samples were coded upon collection and analyzed in a blinded manner in the Krammer laboratory.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    The IgG antibodies to SARS-CoV-2 present in the sample bind to the SARS-CoV-2 antigen coated microparticles.
    IgG
    suggested: None
    Paired t-test for comparison of phase 1 and phase 2 antibody levels was used.
    phase 2
    suggested: None
    Software and Algorithms
    SentencesResources
    Data was analyzed using GraphPad Prism 7.
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)
    Only samples positive in Abbott Architect CMIA The Architect test (Abbott Laboratories) consists of an automated, two-step, qualitative CMIA for qualitatively detecting IgG against the nucleoprotein (N) antigen from SARS-CoV-2.
    Abbott Architect
    suggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)
    Abbott Laboratories
    suggested: None
    Statistical analyses were performed using Prism (GraphPad, USA).
    Prism
    suggested: (PRISM, RRID:SCR_005375)
    GraphPad
    suggested: (GraphPad Prism, RRID:SCR_002798)
    Seroprevalence in this set of samples using a research grade ELISA from Mount Sinai was 28.4%, (142/501), 28.1%, using the SeroKlir test from Kantaro Biosciences (141/501) and 27.3% using the Abbott Architect test (137/501) (Fig. 1A)
    Abbott
    suggested: (Abbott, RRID:SCR_010477)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.02.24.21252340 on medRxiv